Seeking Alpha
 

Pfizer Inc. (PFE)

- NYSE
  • Mar. 16, 2012, 5:50 PM
    Pfizer's (PFE) efforts to divest its infant nutrition and animal health businesses make it a buy, says T. Rowe Price fund manager Mark Finn, who notes the drugmaker trades at a 9x forward P/E and sports a 4% dividend yield. Finn also likes LyondellBasell (LYB), arguing the chemical maker will get a boost from low natural gas prices, and could eventually earn $7-$8/share.
    | Comment!
  • Mar. 15, 2012, 7:34 AM
    The much-discussed offloading by Pfizer (PFE) of its animal-health and infant nutrition business should occur by the middle of next year, according to CEO Ian Read. The company has JPMorgan exploring options for the sales, with estimates ranging as high as a $30B payday for Pfizer after the two separate deals close.
    | Comment!
  • Mar. 12, 2012, 11:05 AM
    Pfizer (PFE +0.4%) says that it's more likely it will spin off its animal-health unit than sell it to one of the host companies (I, II, III) rumored to be in the hunt to buy it. CEO Ian Read notes that it's the largest animal health business and would benefit PFE investors as a stand alone company.
    | 1 Comment
  • Mar. 7, 2012, 5:58 PM
    Novartis (NVS) reportedly made a preliminary offer to buy Pfizer's (PFE) animal-health business but was rebuffed. The offer was made within the past month or so and valued the unit as high as $16B. Bayer (BAYRY.PK) also has expressed interest, but PFE may still be leaning toward a spinoff because of the large tax bill and antitrust scrutiny an outright sale would trigger.
    | Comment!
  • Mar. 7, 2012, 4:58 PM
    Eight big drugmakers - ABT, AMGN, AZN, BMY, GSK, MRK, NVS, PFE - are sued by a consumer group claiming the companies’ coupon programs, which cover much of the patient co-payment for hundreds of brand-name prescription medicines, are illegal.
    | 3 Comments
  • Mar. 7, 2012, 3:13 PM
    Bayer (BAYRY.PK) contemplates making a bid for Pfizer's (PFE +0.9%) animal-health unit in the neighborhood of $14B-$18B, according to research firm Leerink Swann. Pfizer has been discussing a potential sale since last summer with a number of companies, although an earlier report tips off that Sanofi may be taking itself off the list.
    | Comment!
  • Mar. 7, 2012, 8:38 AM
    French drugmaker Sanofi (SNY) is looking to expand in emerging markets and will "probably not" be a bidder for Pfizer's (PFE) animal health business, CEO Chris Viehbacher says. Also, after resuming shipments of the rare disease drug Fabrazyme last week, SNY expects to resume supplying European patients with full doses of the drug by "about mid-year." SNY +0.8% premarket.
    | Comment!
  • Mar. 4, 2012, 5:08 AM
    U.S. companies continued to hoard their foreign profits as they await a tax holiday that may not come or a change in the law. The untaxed overseas income of 70 U.S. corporation climbed by $187B over the past year, a Bloomberg analysis finds, with GE and Pfizer (PFE) leading the way. In total, the U.S. firms hold $1.2T abroad.
    | 4 Comments
  • Feb. 29, 2012, 7:45 AM
    Galapagos CEO Onno van de Stolpe calls the development deal with Abbott Laboratories (ABT) announced earlier today the "largest Phase 2 deal in the history of the industry." The agreement will line up Abbott in competition with Pfizer (PFE) in a race to develop a widely used rheumatoid arthritis drug. Shares of Galapagos are up 22% in Brussels trading.
    | 2 Comments
  • Feb. 28, 2012, 2:45 PM
    The FDA announces important labeling changes for cholesterol-lowering statins, including a warning about increased risk of increased blood sugar levels and of being diagnosed with type 2 diabetes. Drugs that will get the warning include Lipitor, Lescol, Pravachol, Crestor, Mevacor, Altoprev, Livalo and Zocor. Pharmas that make some of the popular drugs: AZN, MRK, PFE.
    | 1 Comment
  • Feb. 27, 2012, 3:39 PM
    Pfizer (PFE +0.8%) agrees to buy closely held Alacer Corp., which makes dietary supplements including the vitamin C product Emergen-C, which will "add to and greatly complement our market-leading dietary supplement portfolio," PFE's consumer healthcare chief says. The unit made up 4.5% of PFE’s 2011 revenue.
    | Comment!
  • Feb. 24, 2012, 2:54 AM
    Mead Johnson (MJN) and Danone (DANOY.PK) land permission to jointly bid for Pfizer's (PFE) $10B infant nutritionals business, sources say. The two firms will go up against Nestle (NSRGY.PK) in the next auction round which closes March 5. (previously)
    | 1 Comment
  • Feb. 21, 2012, 3:19 AM
    Pfizer (PFE) is exploring partnerships with more Chinese drug companies as it tries to expand its marketshare in generic drugs, and reported progress over the weekend in a planned JV with China's Zhejiang Hisun Pharmaceutical. Big Pharma is increasingly turning to China to cut costs and to compensate for sales lost in Western markets as top-selling drugs go off patent.
    | Comment!
  • Feb. 20, 2012, 4:17 AM
    Pfizer (PFE) is reportedly weighing plans to raise around $3B through a partial-flotation of its animal health unit, which is valued at up to $18B. The company, which could use this as a step toward spinning off the unit, is discussing an autumn IPO of 19.9% of the division. (previously)
    | Comment!
  • Feb. 17, 2012, 7:55 PM
    More than 8 months after it signed a memorandum of understanding regarding the deal, Pfizer (PFE) says it has signed a "framework agreement" with China's Hisun Pharmaceutical to create a JV that would produce generic drugs for China and other markets. Hisun will own 51% of the JV, and Pfizer 49%.
    | Comment!
  • Feb. 17, 2012, 1:14 PM
    Nestle (NSRGY.PK) and Danone (DANOY.PK) have submitted preliminary bids of ~$10B for Pfizer's (PFE) infant nutrition business, according to Bloomberg, in-line with the unit's estimated value. However, with the bids likely to face regulatory hurdles, Nestle is said to be considering making asset sales as part of any deal, while Danone is reportedly considering a joint bid with Mead Johnson (MJN).
    | Comment!
Visit Seeking Alpha's
PFE vs. ETF Alternatives
Company Description
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.